POS1457-HPR 7-YEAR PERSISTENCE OF ANTI-TNF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND IMPACT ON DISEASE ACTIVITY
Authors: P. Santos-Moreno, P. Rodríguez-Linares, W. Rivero, G. S. Rodríguez-Vargas, F. Rodriguez-Florido, S. Martinez, L. Ibata, L. Villarreal, A. Rojas-Villarraga, N. Gutiérrez
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Rheumatoid arthritis (RA) is a persistent inflammatory condition that impacts synovial joints, leading to impairment cartilage, erosion bones, and systemic implications. This disease requires a strict control evaluating disease activity, and management is under conventional (csDMARDs) and biological (bDMARDs) treatment. Therefore, the measurement of the treatment persistence is essential to assess the effectiveness of therapy in real-life. <h3>Objectives:</h3> To assess the treatment persistence of three anti-TNF drugs infliximab, etanercept and adalimumab on disease activity in patients with RA. <h3>Methods:</h3> This is a longitudinal, observational, retrospective cohort study in a multidisciplinary healthcare RA program. Data were collected for each patient from clinical records. Databases from 2010 to 2018 were analyzed between January to May 2023. Data from 2020 – 2022 were not taking in to account because COVID-19 pandemic potential bias. Frequencies and proportions in baseline characteristics were calculated in each treatment group and in overall population. For the follow-up of the disease activity, the value of the earliest DAS28 available was reviewed and the annual data was collected. Chi-square test and Fisher's exact test were used for statistical analyses of categorical variables. For the analysis of persistence on treatment, Kaplan Meier method was used. <h3>Results:</h3> There were 183 RA patients included (80% women, median age 60 years), who received adalimumab (n=56), etanercept (n=64), or infliximab (n=63) during the 7-year study period. At the first year of treatment, 67% to 87% of the cohorts achieved disease activity control and disease response to treatment. At the third year, 95% to 98% of subjects on anti-TNFs continued with the medication. In year 5, the proportion of patients on medication was maintained in 80%-90%, but at 7 years decreased to 42-54%. Median treatment persistence for the all groups was 88 months (95%CI 87.3 to 88.7), 87 months (95%CI 86.2 to 87.8) and 89 months (95%CI 88.4 to 89.6) for adalimumab, etanercept and infliximab, respectively (Figure 1). In the analysis of effectiveness, a reduction in disease activity, measured by DAS28, was evidenced in all cohorts with biological treatment, particularly in the first 2 years of therapy and maintained over time for up to 7 years (Table 1). <h3>Conclusion:</h3> Anti-TNF effectiveness and persistence was similar among 3 molecules evaluated and maintained very well until years 5 - 7. These findings shows that under environment of a multidisciplinary care RA program the treatment persistence with anti-TNFs could be maintained long time during the course of the disease. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Pedro Santos-Moreno Abbvie, Abbott, Biopas-UCB, Bristol, Janssen, Pfizer, Roche, Sanofi, Abbvie, Abbott, Biopas-UCB, Bristol, Janssen, Pfizer, Roche, Sanofi, Pedro Rodríguez-Linares: None declared, Wilberto Rivero: None declared, Gabriel-Santiago Rodríguez-Vargas: None declared, Fernando Rodriguez-Florido: None declared, Susan Martinez: None declared, Linda Ibata: None declared, Laura Villarreal: None declared, Adriana Rojas-Villarraga: None declared, Nicolás Gutiérrez: None declared.